Genentech on Tuesday said first-quarter profit rose 48% on strong sales of Avastin and its other cancer medicines, and it raised its earnings forecast for the full year.
*For more on this story,
read the full Reuters article.
Genentech on Tuesday said first-quarter profit rose 48% on strong sales of Avastin and its other cancer medicines, and it raised its earnings forecast for the full year.
*For more on this story,
read the full Reuters article.
Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!
One-Year for Only $99